Apr 12, 2016

Posted by in Biotech Stocks | 0 Comments

Watch List: Insys Therapeutics Inc (NASDAQ:INSY), Relypsa Inc (NASDAQ:RLYP), Opko Health Inc. (NYSE:OPK)

Watch List: Insys Therapeutics Inc (NASDAQ:INSY), Relypsa Inc (NASDAQ:RLYP), Opko Health Inc. (NYSE:OPK)

Insys Therapeutics Inc (NASDAQ:INSY) stock is at $14.24, down -19.37 percent from its previous close of $17.66. The stock opened the session at $14.95 and touched its highest price point at $15.33. The company’s stock’s lowest price point for the session stood at $13.20. Its yesterday’s volume is 3.94 million shares in comparison to its usual trading volume of 728,170.00 shares.

Insys Therapeutics Inc (NASDAQ:INSY) on April 11, 2016 announced that its preliminary estimated revenues from Subsys® (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 million to $62 million. Estimated revenues for the quarter reflect a decline in demand, as Subsys prescription volumes were down, as well as a reduction in wholesale inventory levels.  The Company estimates the decrease in wholesale channel inventory levels to be in the range of $7 million.

The Company believes that heightened publicity surrounding the national opioid epidemic has resulted in a sensitivity by some healthcare providers to prescribe opioids.  The Company expects the Subsys prescription decline is close to stabilizing.  At the current sales levels, the Company believes it will remain profitable and intends to pursue all of its research and development projects.

Relypsa Inc (NASDAQ:RLYP) stock is at $22.73, up +1.11 percent from its previous close of $22.48. Its yesterday’s volume is 3.90 million shares in comparison to its usual trading volume of 2.65 million shares. Previous 5 days graph demonstrated a positive move of 66.4%. Its quarterly performance remained green with the percentage of 15.97, while its year to date performance showed that the stock plunged overall -21.08%.

Relypsa Inc (NASDAQ:RLYP) on April 6, 2016 announced that on April 1, 2016 the compensation committee of the company’s board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company’s common stock with a per share exercise price of $13.30, the closing trading price on the grant date, and 3,725 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.

Opko Health Inc. (NYSE:OPK) traded in the range of $10.70 and $11.07 in its previous trading session. The stock recorded the volume of 3.20 million shares so far, in comparison its average daily trading volume of 4.73 million shares. Company’s year to date performance remained quiet optimistic with the rise of 6.02%. The stock opened at $10.79 and its closing price for the day was $11.07, up +0.19 percent from its previous close.

Opko Health Inc. (NYSE:OPK) on March 28, 2016 announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.

Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.

“Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO.

 

Comments are closed.